Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Lipotoxicity and the development of heart failure: moving from mouse to man.

Stanley WC, Recchia FA.

Cell Metab. 2010 Dec 1;12(6):555-6. doi: 10.1016/j.cmet.2010.11.016.

2.

Downregulation of peroxisome proliferator-activated receptor-alpha gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species and prevents lipotoxicity.

Dewald O, Sharma S, Adrogue J, Salazar R, Duerr GD, Crapo JD, Entman ML, Taegtmeyer H.

Circulation. 2005 Jul 19;112(3):407-15. Epub 2005 Jul 11.

3.

Astragalus polysaccharides repress myocardial lipotoxicity in a PPARalpha-dependent manner in vitro and in vivo in mice.

Chen W, Lai Y, Wang L, Xia Y, Chen W, Zhao X, Yu M, Li Y, Zhang Y, Ye H.

J Diabetes Complications. 2015 Mar;29(2):164-75. doi: 10.1016/j.jdiacomp.2014.11.007. Epub 2014 Nov 25.

PMID:
25499591
4.

A mouse model reveals an important role for catecholamine-induced lipotoxicity in the pathogenesis of stress-induced cardiomyopathy.

Shao Y, Redfors B, Ståhlman M, Täng MS, Miljanovic A, Möllmann H, Troidl C, Szardien S, Hamm C, Nef H, Borén J, Omerovic E.

Eur J Heart Fail. 2013 Jan;15(1):9-22. doi: 10.1093/eurjhf/hfs161. Epub 2012 Oct 25.

5.

PPARγ-induced cardiolipotoxicity in mice is ameliorated by PPARα deficiency despite increases in fatty acid oxidation.

Son NH, Yu S, Tuinei J, Arai K, Hamai H, Homma S, Shulman GI, Abel ED, Goldberg IJ.

J Clin Invest. 2010 Oct;120(10):3443-54. doi: 10.1172/JCI40905. Epub 2010 Sep 13. Erratum in: J Clin Invest. 2010 Dec 1;120(12):4583.

6.

Therapy with Astragalus polysaccharides rescues lipotoxic cardiomyopathy in MHC-PPARα mice.

Chen W, Chen W, Xia Y, Zhao X, Wang H, Yu M, Li Y, Ye H, Zhang Y.

Mol Biol Rep. 2013 Mar;40(3):2449-59. doi: 10.1007/s11033-012-2325-1. Epub 2012 Nov 30.

PMID:
23196711
7.

Bilobetin ameliorates insulin resistance by PKA-mediated phosphorylation of PPARα in rats fed a high-fat diet.

Kou XH, Zhu MF, Chen D, Lu Y, Song HZ, Ye JL, Yue LF.

Br J Pharmacol. 2012 Apr;165(8):2692-706. doi: 10.1111/j.1476-5381.2011.01727.x.

8.

Cardiac expression of microsomal triglyceride transfer protein is increased in obesity and serves to attenuate cardiac triglyceride accumulation.

Bartels ED, Nielsen JM, Hellgren LI, Ploug T, Nielsen LB.

PLoS One. 2009;4(4):e5300. doi: 10.1371/journal.pone.0005300. Epub 2009 Apr 23.

9.

Failing heart of patients with type 2 diabetes mellitus can adapt to extreme short-term increases in circulating lipids and does not display features of acute myocardial lipotoxicity.

Nielsen R, Nørrelund H, Kampmann U, Kim WY, Ringgaard S, Schär M, Møller N, Bøtker HE, Wiggers H.

Circ Heart Fail. 2013 Jul;6(4):845-52. doi: 10.1161/CIRCHEARTFAILURE.113.000187. Epub 2013 Jun 3.

10.

Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism.

Gilde AJ, van der Lee KA, Willemsen PH, Chinetti G, van der Leij FR, van der Vusse GJ, Staels B, van Bilsen M.

Circ Res. 2003 Mar 21;92(5):518-24. Epub 2003 Feb 6.

11.

Triglyceride accumulation protects against fatty acid-induced lipotoxicity.

Listenberger LL, Han X, Lewis SE, Cases S, Farese RV Jr, Ory DS, Schaffer JE.

Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3077-82. Epub 2003 Mar 10.

12.

Effects of chronic activation of peroxisome proliferator-activated receptor-alpha or high-fat feeding in a rat infarct model of heart failure.

Morgan EE, Rennison JH, Young ME, McElfresh TA, Kung TA, Tserng KY, Hoit BD, Stanley WC, Chandler MP.

Am J Physiol Heart Circ Physiol. 2006 May;290(5):H1899-904. Epub 2005 Dec 9.

13.

Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver.

Park SY, Cho YR, Finck BN, Kim HJ, Higashimori T, Hong EG, Lee MK, Danton C, Deshmukh S, Cline GW, Wu JJ, Bennett AM, Rothermel B, Kalinowski A, Russell KS, Kim YB, Kelly DP, Kim JK.

Diabetes. 2005 Sep;54(9):2514-24.

14.

Cardiac-specific ablation of ARNT leads to lipotoxicity and cardiomyopathy.

Wu R, Chang HC, Khechaduri A, Chawla K, Tran M, Chai X, Wagg C, Ghanefar M, Jiang X, Bayeva M, Gonzalez F, Lopaschuk G, Ardehali H.

J Clin Invest. 2014 Nov;124(11):4795-806. doi: 10.1172/JCI76737. Epub 2014 Oct 20.

15.

A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content.

Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, Kelly DP.

Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1226-31. Epub 2003 Jan 27.

16.

The role of cardiac lipotoxicity in the pathogenesis of diabetic cardiomyopathy.

Ussher JR.

Expert Rev Cardiovasc Ther. 2014 Mar;12(3):345-58. doi: 10.1586/14779072.2014.891939. Epub 2014 Feb 19. Review.

PMID:
24552544
17.

Rescue of cardiac leptin receptors in db/db mice prevents myocardial triglyceride accumulation.

Hall ME, Maready MW, Hall JE, Stec DE.

Am J Physiol Endocrinol Metab. 2014 Aug 1;307(3):E316-25. doi: 10.1152/ajpendo.00005.2014. Epub 2014 Jun 17.

18.

Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice.

Son NH, Park TS, Yamashita H, Yokoyama M, Huggins LA, Okajima K, Homma S, Szabolcs MJ, Huang LS, Goldberg IJ.

J Clin Invest. 2007 Oct;117(10):2791-801.

19.

Adipogenesis and lipotoxicity: role of peroxisome proliferator-activated receptor gamma (PPARgamma) and PPARgammacoactivator-1 (PGC1).

Medina-Gomez G, Gray S, Vidal-Puig A.

Public Health Nutr. 2007 Oct;10(10A):1132-7. Review.

PMID:
17903321
20.

Peroxisome proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats.

Shin SJ, Lim JH, Chung S, Youn DY, Chung HW, Kim HW, Lee JH, Chang YS, Park CW.

Hypertens Res. 2009 Oct;32(10):835-45. doi: 10.1038/hr.2009.107. Epub 2009 Jul 31.

PMID:
19644507

Supplemental Content

Support Center